PMID- 17387458
OWN - NLM
STAT- MEDLINE
DCOM- 20070906
LR  - 20220716
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 193
IP  - 1
DP  - 2007 Jul
TI  - MDMA attenuates THC withdrawal syndrome in mice.
PG  - 75-84
AB  - INTRODUCTION: 3, 4-Methylenedioxymethamphetamine (MDMA) and cannabis are widely 
      abused illicit drugs that are frequently consumed in combination. Interactions 
      between these two drugs have been reported in several pharmacological responses 
      observed in animals, such as body temperature, anxiety, cognition, and reward. 
      However, the interaction between MDMA and cannabis in addictive processes such as 
      physical dependence has not been elucidated yet. DISCUSSION: In this study, the 
      effects of acute and chronic MDMA were evaluated on the behavioral manifestations 
      of Delta(9)-tetrahydrocannabinol (THC) abstinence in mice. THC withdrawal 
      syndrome was precipitated by injecting the cannabinoid antagonist rimonabant (10 
      mg/kg, i.p.) in mice chronically treated with THC and receiving MDMA (2.5, 5 and 
      10 mg/kg i.p.) or saline just before the withdrawal induction or chronically 
      after the THC administration. RESULTS: Both chronic and acute MDMA decreased in a 
      dose-dependent manner the severity of THC withdrawal. In vivo microdialysis 
      experiments showed that acute MDMA (5 mg/kg, i.p.) administration increased 
      extracellular serotonin levels in the prefrontal cortex, but not dopamine levels 
      in the nucleus accumbens. Our results also indicate that the attenuation of THC 
      abstinence symptoms was not due to a direct interaction between rimonabant and 
      MDMA nor to the result of the locomotor stimulating effects of MDMA. CONCLUSION: 
      The modulation of the cannabinoid withdrawal syndrome by acute or chronic MDMA 
      suggests a possible mechanism to explain the associated consumption of these two 
      drugs in humans.
FAU - Tourino, Clara
AU  - Tourino C
AD  - Grup de Recerca de Neurobiologia del Comportament, Departament de Ciencies 
      Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, C/ Dr. Aiguader 80, 
      08003, Barcelona, Spain.
FAU - Maldonado, Rafael
AU  - Maldonado R
FAU - Valverde, Olga
AU  - Valverde O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070327
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Cannabinoid Receptor Antagonists)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 333DO1RDJY (Serotonin)
RN  - 7J8897W37S (Dronabinol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - RML78EN3XE (Rimonabant)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/metabolism
MH  - Cannabinoid Receptor Antagonists
MH  - Dopamine/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Dronabinol/*adverse effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*therapeutic use
MH  - Piperidines/pharmacology
MH  - Pyrazoles/pharmacology
MH  - Rimonabant
MH  - Serotonin/metabolism
MH  - Substance Withdrawal Syndrome/*drug therapy/physiopathology
EDAT- 2007/03/28 09:00
MHDA- 2007/09/07 09:00
CRDT- 2007/03/28 09:00
PHST- 2006/09/29 00:00 [received]
PHST- 2007/03/10 00:00 [accepted]
PHST- 2007/03/28 09:00 [pubmed]
PHST- 2007/09/07 09:00 [medline]
PHST- 2007/03/28 09:00 [entrez]
AID - 10.1007/s00213-007-0772-5 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2007 Jul;193(1):75-84. doi: 10.1007/s00213-007-0772-5. 
      Epub 2007 Mar 27.